Screening during pregnancy
is aimed at assessing the risk that a fetus may have a particular
genetic or congenital condition or that a pregnant woman has, or
is at risk of having, a condition or complication of pregnancy that
may affect the wellbeing of herself or her fetus. Once the risk
is assessed, further diagnostic tests may be offered/carried out.
What information
do we have about the Eastern Board area?
The National Screening
Committee (NSC) advises Government on screening policy and quality
assurance. Currently the NSC supports screening during pregnancy
for the following conditions:
Maternal Conditions
Anaemia
Hepatitis B
HIV
Syphilis
Pre-eclampsia
Rubella immunity
Fetal Conditions
Neural tube defect
Down’s Syndrome
Fetal anomalies
Haemoglobinopathies and
Sickle Cell Disease
Haemolytic disease of the
newborn
Tay Sachs Disease (for
high risk populations)
Condition
Frequency
Impact of screening on health
Anaemia
1 in 10 pregnancies
Intervention reduces likelihood
of anaemia at term
Hepatitis B
1 in 300 pregnancies1
Intervention including neonatal
vaccination substantially reduces the risk of infection in infant
HIV
1 in 3000 pregnancies1
Intervention substantially reduces
the risk of infection in the infant
Syphilis
1 in 5000 pregnancies2
Intervention substantially reduces
risk of congenital syphilis in the infant
Pre-eclampsia
1 in 10 to 1 in 50 pregnancies
Reduces risk of morbidity and
mortality for fetus and mother
Rubella immunity
1 in 100 pregnancies1
Vaccination offered to non-immune
women reduces risk of congenital rubella syndrome in future
pregnancies
Neural Tube Defect
1 in 1000 pregnancies
Informed decisions regarding
pregnancy
Down’s Syndrome
1-2 per 1000 pregnancies, increases
with maternal age
(1 in 100 for women aged 40)
Informed decisions regarding
pregnancy
Fetal anomalies
1 in 50 births (includes minor
anomalies)
Informed decisions regarding
pregnancy
Haemoglobinopathies & Sickle
Cell Disease
1 in 2000 to10,000 pregnancies
Informed decisions regarding
pregnancy
Haemolytic disease of the newborn
In 1 in 10 births the fetus is
RhD positive and the mother RhD negative. Prior to screening
1% of all births were affected by haemolytic disease, with one
death in every 2200 births
Early diagnosis and prophylaxis/interventions
has reduced the frequency of affected infants to 1 in 21,000
births. Implementation of routine antenatal anti-D prophylaxis
in 2004 is expected to reduce further the associated morbidity
and mortality
Tay Sachs Disease
1 in 3600 births among Ashkenazi
Jewish populations
For some conditions (e.g. anaemia,
hepatitis B, HIV, syphilis, pre-eclampsia, haemolytic disease of the
newborn), early diagnosis and appropriate treatment can improve the
outcome for the fetus and/or mother. In other conditions screening
allows parents to make informed decisions regarding the pregnancy.
Screening can never be 100% accurate, i.e.
it cannot identify all cases. ‘Abnormal’ results may
occur among pregnant women/pregnancies who do not have the condition
being screened for (false positives). Thus screening may result
in unnecessary anxiety and investigations, which may have adverse
effects.
In
Northern Ireland the policy of the Department of Health, Social
Services & Public Safety is for the following screening programmes
to be offered to all pregnant women:
Anaemia
Hepatitis B
HIV
Syphilis
Pre-eclampsia
Rubella immunity
Haemolytic disease of the newborn
Screening for the following conditions is currently
under review:
Eastern Health and Social Services Board Champion
House, 12-22 Linenhall Street, Belfast BT2 8BS Telephone: (028)
9032 1313 Fax: (028) 9055 3681 Text Phone:(028) 9032 4980 Website:
www.ehssb.org
E-mail: pr@ehssb.n-i.nhs.uk
Site designed by areema.co.uk